Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Merlo, Sebastjan"'
Modern approach to the management of genitourinary syndrome in women with gynecological malignancies
Publikováno v:
Radiology and Oncology, Vol 57, Iss 3, Pp 292-298 (2023)
The term genitourinary syndrome of menopause was first used in 2014 by the North American Menopause Society and the International Society for the Study of Women's Sexual Health to describe conditions previously known as atrophic vaginitis, urogenital
Externí odkaz:
https://doaj.org/article/b4bd4bea97d841ed9ff5a12229299bbd
Autor:
Vivod Gregor, Jesenko Tanja, Gasljevic Gorana, Kovacevic Nina, Bosnjak Masa, Sersa Gregor, Merlo Sebastjan, Cemazar Maja
Publikováno v:
Radiology and Oncology, Vol 57, Iss 1, Pp 121-126 (2023)
Electrochemotherapy has good local effectiveness in the treatment of vulvar cancer. Most studies have reported the safety and effectiveness of electrochemotherapy for palliative treatment of gynecological cancers and mostly vulvar squamous cell carci
Externí odkaz:
https://doaj.org/article/9eaddd6160d7433da811bfec7668769b
Publikováno v:
Radiology and Oncology, Vol 55, Iss 3, Pp 341-346 (2021)
Ovarian cancer is the seventh most common cancer in women worldwide and the eighth most common cause of cancer death. Due to the lack of effective early detection strategies and the unspecific onset of symptoms, it is diagnosed at an advanced stage i
Externí odkaz:
https://doaj.org/article/34178df50b164b7eace657ea8d075c6f
Autor:
Merlo Sebastjan
Publikováno v:
Radiology and Oncology, Vol 54, Iss 4, Pp 371-376 (2020)
Vulvar cancer accounts for 3–5% of malignant diseases of the female genital tract. The Slovenian incidence rate is 5.5/100,000, which means 57 new cases per year. The most common histological type (90%) is squamous cell carcinoma. Based on etiology
Externí odkaz:
https://doaj.org/article/ec9cd87d4173491fa855ada69fdc1884
Publikováno v:
Radiology and Oncology, Vol 50, Iss 3, Pp 341-346 (2016)
Primary treatment of patients with advanced epithelial ovarian cancer consists of chemotherapy either before (neoadjuvant chemotherapy, NACT) or after primary surgery (adjuvant chemotherapy). The goal of primary treatment is no residual disease after
Externí odkaz:
https://doaj.org/article/92402ef982d94bb69fde89848a898da3